TextPurpose: Endometrial cancer (EC) is the commonest gynaecological cancer in the UK. Type I ECs are oestrogen sensitive, develop from premalignant hyperplasia and are low-medium grade. Type II ECs arise de novo, are high grade and have a worse prognosis. Given the role of prostaglandinendoperoxide synthase (PTGS; cyclooxygenase) products prostaglandin (PG)F2 alpha and PGE2 in cancer, this study profiled them and their synthetic/catabolic enzymes in EC carcinogenesis.Methods: PTGS1 and PTGS2 expression profiles were assessed by genome-wide expression microarray of laser capture microdissected endometrial specimens (n=81 normal, 30 hyperplastic, 118 cancerous). Matched tissue samples were analysed by mass spectrometry for PGF2 alpha, PGE2 and its inactive metabolite dihydro-15-keto PGE2 and normalised to protein. Tissue microarrays (n=419 ECs) were immunohistochemically stained for PTGS1, PTGS2 and the PG catabolic enzyme hydroxyprostaglandin dehydrogenase (HPGD).
Neuroendocrine tumors (NETs) are not commonly diagnosed in children. Metastatic NETs tend to have poor outcomes, and this is seen in adult and pediatric populations. The role of somatostatin receptor imaging using [68Ga]Ga-DOTA-TATE for imaging and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE in children is currently not well established. The guidelines for treating pediatric neuroendocrine tumors are still lacking. Extensive trials have been conducted in adult patients and have demonstrated improved survival in metastatic NETs with PRRT using [177Lu]Lu-DOTA-TATE. We present two pediatric patients with metastatic NETs who were imaged with [68Ga]Ga-DOTA-TATE PET/CT and treated with [177Lu]Lu-DOTA-TATE therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.